Advanced in Clear Cell Sarcoma

Dr. Paul R. Conkling

Hematology | Oncology
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
Accepting New Patients
Advanced in Clear Cell Sarcoma
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Conkling is a Hematologist and an Oncologist in Newport News, Virginia. Dr. Conkling is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Anal Cancer. Dr. Conkling is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Specialist in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Optima Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

VIRGINIA ONCOLOGY ASSOCIATES
1051 Loftis Blvd, Suite 100, Newport News, VA 23606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 9 Less Clinical Trials

31 Total Publications

Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Journal: JCO clinical cancer informatics
Published: March 05, 2025
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Mark T. Fleming
Hematology Oncology | Hematology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Mark T. Fleming
Hematology Oncology | Hematology | Oncology

Virginia Oncology Associates

3000 Coliseum Dr, Suite 104, 
Hampton, VA 
 (5.6 miles away)
757-827-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Fleming is a Hematologist Oncology specialist and a Hematologist in Hampton, Virginia. Dr. Fleming is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Pancreaticoduodenectomy, and Orchiectomy. Dr. Fleming is currently accepting new patients.

Advanced in Clear Cell Sarcoma
Dr. Daniel M. Atienza
Hematology Oncology | Hematology | Oncology
Advanced in Clear Cell Sarcoma
Dr. Daniel M. Atienza
Hematology Oncology | Hematology | Oncology

Virginia Oncology Associates

5838 Harbour View Blvd, Suite 105, 
Suffolk, VA 
 (15.0 miles away)
757-484-0215
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Atienza is a Hematologist Oncology specialist and a Hematologist in Suffolk, Virginia. Dr. Atienza is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Colorectal Cancer, Paget Disease of the Breast, Lung Cancer, and Monoclonal Gammopathy of Undetermined Significance (MGUS).

Advanced in Clear Cell Sarcoma
Dr. Aisha S. Zaidi
Hematology Oncology | Oncology | Hematology
Advanced in Clear Cell Sarcoma
Dr. Aisha S. Zaidi
Hematology Oncology | Oncology | Hematology

Virginia Cancer Institute Incorporated

7492 Right Flank Rd, 
Mechanicsville, VA 
 (61.0 miles away)
804-559-2489
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aisha Zaidi is a Hematologist Oncology specialist and an Oncologist in Mechanicsville, Virginia. Dr. Zaidi is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Paget Disease of the Breast, Vitamin D Deficiency, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Zaidi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Conkling's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile